By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

GeNeuro 

18, chemin des Aulx,

Plan-les-Ouates  Geneva  CH-1228  Switzerland
Phone: 41-22-794-50-85 Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
GeNeuro And Servier Announce Six-Month Results From CHANGE-MS Phase IIb Study In Multiple Sclerosis 8/28/2017 8:20:15 AM
GeNeuro Announces First Patient Treated In Phase IIa Study With Gnbac1 In Type 1 Diabetes 6/19/2017 5:20:02 AM
GeNeuro Initiates Phase IIa Study With Gnbac1 In Type 1 Diabetes In Australia 4/19/2017 1:12:47 PM
GeNeuro Signs CRADA Agreement With NIH To Develop Novel Antibody Treatment For ALS 2/8/2017 7:56:32 AM
GeNeuro Announces First Patients Treated In Phase 2b Study For Multiple Sclerosis 6/1/2016 1:02:06 PM
GeNeuro Announces First Patients Treated In Phase IIb Study For Multiple Sclerosis 5/31/2016 11:01:03 AM
GeNeuro Announces The Launch Of Phase IIb Proof-Of-Concept Study With Gnbac1 In Multiple Sclerosis And Servier Equity Investment 12/18/2015 11:11:11 AM
GeNeuro Appoints Dr. Gordon Francis And Giacomo Di Nepi To Board Of Directors 5/5/2015 11:05:35 AM
GeNeuro, Servier Ink $455M MS Drug Pact 12/2/2014 6:47:52 AM
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach To Treat Multiple Sclerosis 9/3/2014 12:26:43 PM
12
//-->